FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016562467> ?p ?o ?g. }

• W2016562467 endingPage "600" @default.
• W2016562467 startingPage "592" @default.
• W2016562467 abstract "The purpose of this work was to study the feasibility of concurrent chemoradiation in patients with inoperable non-small cell lung cancer (NSCLC). 40 patients with inoperable NSCLC were treated with escalating doses of radiotherapy and cisplatin (cDDP). The radiation dose was increased step by step from 60.5 to 66 Gy in daily fractions of 2.75 Gy. Chemotherapy was also increased step by step from 20 to 24 daily doses of cDDP 6 mg/m(2) and given concurrently with radiotherapy. A dose of 40 Gy/2 Gy/20 fractions (fx) was given to the EPTV (elective planning target volume) which included the gross tumour volume with a margin of 2 cm and part of or the entire mediastinum. During each session a boost dose of 0.75 Gy was given simultaneously to the BPTV (boost planning target volume), which encompassed the GTV (gross tumour volume) with a margin of 1 cm, for the first 20 fx, so the total dose to the tumour was 55 Gy. Cisplatin 6 mg/m(2) was given 1 h prior to radiotherapy at each fraction. From then on the dose of radiation to the BPTV and the dose of cDDP were increased step by step. In group I the BPTV was irradiated with two extra fractions of 2.75 Gy to a total dose of 60. 5 Gy without cDDP. In group II the same total dose of 60.5 Gy was given but the last two fractions were combined with cDDP. In group III four extra fractions of 2.75 Gy were given to the BPTV to a total dose of 66 Gy, only two of these fractions combined with cDDP. Finally, in group IV a total dose of 66 Gy was given in 24 fractions, all fractions combined with cDDP. All patients were planned by means of a CT-based conformal treatment planning. The maximal length of the oesophagus receiving >/=60.5 Gy was 11 cm. 40 patients were evaluable for acute and late toxicity and for survival. Acute toxicity grade >/=3 (common toxicity criteria, CTC) was rarely observed; nausea/vomiting in 3 patients (8%), leucopenia in 2 patients (5%), thrombocytopenia in 2 patients (5%), whilst 2 patients (5%) suffered from severe weight loss. Late side-effects (European Organization for Research and Treatment of Cancer/Radiation Therapy Oncology Group, EORTC/RTOG) were: oesophageal toxicity >/=grade 3 in 2 patients (5%) and radiation pneumonitis grades 1 (3%) and 2 (3%) in 1 patient each. Overall actuarial 1- and 2-year survival was 53% and 40%, respectively. The 1- and 2-year local disease-free interval was 65% and 58% respectively. Radiotherapy at a dose of 66 Gy/2.75 Gy/24 fx combined with daily cDDP 6 mg/m(2) given over 5 weeks is feasible and results in a good local disease-free interval and a good survival rate. This treatment schedule is at present being tested as one of the two treatment arms of EORTC phase III study protocol 08972/22973." @default.
• W2016562467 created "2016-06-24" @default.
• W2016562467 creator A5017255382 @default.
• W2016562467 creator A5018342179 @default.
• W2016562467 creator A5027573670 @default.
• W2016562467 creator A5052010430 @default.
• W2016562467 creator A5067054454 @default.
• W2016562467 creator A5068893119 @default.
• W2016562467 creator A5071909458 @default.
• W2016562467 creator A5077313682 @default.
• W2016562467 creator A5090775166 @default.
• W2016562467 date "2000-03-01" @default.
• W2016562467 modified "2023-10-15" @default.
• W2016562467 title "Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer" @default.
• W2016562467 cites W1930978022 @default.
• W2016562467 cites W1978156658 @default.
• W2016562467 cites W1983262493 @default.
• W2016562467 cites W1986884101 @default.
• W2016562467 cites W1994848379 @default.
• W2016562467 cites W2002261289 @default.
• W2016562467 cites W2014145691 @default.
• W2016562467 cites W2016694541 @default.
• W2016562467 cites W2018892965 @default.
• W2016562467 cites W2019926572 @default.
• W2016562467 cites W2020687877 @default.
• W2016562467 cites W2021775131 @default.
• W2016562467 cites W2026788229 @default.
• W2016562467 cites W2027381633 @default.
• W2016562467 cites W2028398018 @default.
• W2016562467 cites W2032991556 @default.
• W2016562467 cites W2037957024 @default.
• W2016562467 cites W2045559867 @default.
• W2016562467 cites W2051767374 @default.
• W2016562467 cites W2057991314 @default.
• W2016562467 cites W2059660774 @default.
• W2016562467 cites W2061581927 @default.
• W2016562467 cites W2066334626 @default.
• W2016562467 cites W2071918875 @default.
• W2016562467 cites W2090812119 @default.
• W2016562467 cites W2097512974 @default.
• W2016562467 cites W2122488895 @default.
• W2016562467 cites W2142764975 @default.
• W2016562467 cites W2149787575 @default.
• W2016562467 cites W2155053061 @default.
• W2016562467 cites W2155256756 @default.
• W2016562467 cites W2162597644 @default.
• W2016562467 cites W2165046000 @default.
• W2016562467 cites W2226077283 @default.
• W2016562467 cites W2312703485 @default.
• W2016562467 cites W2314753133 @default.
• W2016562467 cites W2324392028 @default.
• W2016562467 cites W2328935341 @default.
• W2016562467 cites W2331395194 @default.
• W2016562467 cites W4230213530 @default.
• W2016562467 cites W4239714259 @default.
• W2016562467 doi "https://doi.org/10.1016/s0959-8049(99)00315-9" @default.
• W2016562467 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10738123" @default.
• W2016562467 hasPublicationYear "2000" @default.
• W2016562467 type Work @default.
• W2016562467 sameAs 2016562467 @default.
• W2016562467 citedByCount "58" @default.
• W2016562467 countsByYear W20165624672012 @default.
• W2016562467 countsByYear W20165624672013 @default.
• W2016562467 countsByYear W20165624672014 @default.
• W2016562467 countsByYear W20165624672015 @default.
• W2016562467 countsByYear W20165624672016 @default.
• W2016562467 countsByYear W20165624672017 @default.
• W2016562467 countsByYear W20165624672018 @default.
• W2016562467 countsByYear W20165624672021 @default.
• W2016562467 countsByYear W20165624672022 @default.
• W2016562467 crossrefType "journal-article" @default.
• W2016562467 hasAuthorship W2016562467A5017255382 @default.
• W2016562467 hasAuthorship W2016562467A5018342179 @default.
• W2016562467 hasAuthorship W2016562467A5027573670 @default.
• W2016562467 hasAuthorship W2016562467A5052010430 @default.
• W2016562467 hasAuthorship W2016562467A5067054454 @default.
• W2016562467 hasAuthorship W2016562467A5068893119 @default.
• W2016562467 hasAuthorship W2016562467A5071909458 @default.
• W2016562467 hasAuthorship W2016562467A5077313682 @default.
• W2016562467 hasAuthorship W2016562467A5090775166 @default.
• W2016562467 hasConcept C126322002 @default.
• W2016562467 hasConcept C126838900 @default.
• W2016562467 hasConcept C126894567 @default.
• W2016562467 hasConcept C143998085 @default.
• W2016562467 hasConcept C2776256026 @default.
• W2016562467 hasConcept C2776694085 @default.
• W2016562467 hasConcept C2778239845 @default.
• W2016562467 hasConcept C2779126056 @default.
• W2016562467 hasConcept C2989005 @default.
• W2016562467 hasConcept C509974204 @default.
• W2016562467 hasConcept C71924100 @default.
• W2016562467 hasConceptScore W2016562467C126322002 @default.
• W2016562467 hasConceptScore W2016562467C126838900 @default.
• W2016562467 hasConceptScore W2016562467C126894567 @default.
• W2016562467 hasConceptScore W2016562467C143998085 @default.
• W2016562467 hasConceptScore W2016562467C2776256026 @default.
• W2016562467 hasConceptScore W2016562467C2776694085 @default.
• W2016562467 hasConceptScore W2016562467C2778239845 @default.

• next